

12 September 2018

ASX Limited  
20 Bridge Street  
Sydney NSW 2000

**ASX ANNOUNCEMENT**

**CLEANSING NOTICE UNDER SECTION 708A(5)e OF THE CORPORATIONS ACT**

Cellmid Limited (Company) has today issued and allotted 21,857,630 fully paid ordinary shares as set out in the Appendix 3B dated today (Shares).

In accordance with section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) the Company advises that:

1. the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
  - a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - b) section 674 of the Corporations Act;
3. as at the date of this notice, there is no excluded information for the purposes of sections 708A(7) and 708A(8) of the Corporations Act.

Yours faithfully

End  
Contact: Maria Halasz, CEO  
T +612 9221 6830

 @mariahalasz

**Cellmid Limited (ASX: CDY)**

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lynamid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining to midkine is being exploited through wholly owned subsidiaries Lynamid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia and Japan, and currently expanding distribution in other territories. For further information, please see [www.cellmid.com.au](http://www.cellmid.com.au), [www.evolisproducts.com.au](http://www.evolisproducts.com.au) and [www.evolisprofessional.com](http://www.evolisprofessional.com).